Glucose Monitoring Without Breaking the Skin: How Close Are We Really?

What if people with diabetes could check their blood sugar without needles or test strips? That possibility is driving interest in noninvasive glucose monitoring, a technology designed to estimate glucose levels without breaking the skin. A recent study evaluated a device that uses near-infrared light in adults with type 2 diabetes. Although early findings are encouraging, important questions remain about accuracy, safety, and whether these devices could eventually replace finger-stick testing or continuous glucose monitors (CGMs).

Table of Contents

1. How Needle-Free Glucose Monitoring Works
2. What the Latest Clinical Study Revealed
3. How Accuracy Compares With Established Glucose Monitors
4. What Comes Next for Needle-Free Glucose Testing
5. Conclusion
6. Frequently Asked Questions

How Needle-Free Glucose Monitoring Works

Traditional blood glucose meters require a small blood sample, usually obtained through a finger stick. Meanwhile, CGM systems use a sensor inserted beneath the skin to measure glucose in interstitial fluid. Both approaches provide valuable information, but some patients find repeated testing uncomfortable or inconvenient.

Newer needle-free devices aim to overcome these barriers by estimating glucose levels without breaking the skin.

One promising approach uses near-infrared spectroscopy, a technology that analyzes how light interacts with body tissues. Different substances absorb and scatter light in distinct ways. Therefore, researchers can study optical signals and use mathematical models to estimate glucose concentrations.

The recently evaluated GLUCUBE device uses this principle. Users place a finger inside the device, which sends near-infrared light through the fingertip. Sensors detect the transmitted light, while specialized software processes the information to estimate glucose levels.

However, glucose signals are difficult to isolate because water, tissue composition, and other biological factors influence light transmission. As a result, personalized calibration is necessary to improve accuracy.

In the study, participants completed 10 paired finger-stick measurements during initial calibration. Afterward, the device could provide on-demand estimates without routine finger-stick testing.

Importantly, this is not continuous measurement. Unlike CGM, the device provides readings when users actively perform a test.

What the Latest Clinical Study Revealed

A 2026 clinical investigation published in the Journal of Diabetes Science and Technology examined GLUCUBE during everyday use among adults with type 2 diabetes.

Researchers enrolled 52 participants in a prospective, single-center study in Spain. Participants performed four paired daily measurements for approximately three weeks, comparing the experimental device with the Ascensia Contour Next blood glucose meter.

Of those enrolled, 48 participants contributed 2,616 paired measurements to the primary analysis after calibration.

The study produced several notable findings.

First, the device achieved a combined mean absolute difference and mean absolute relative difference (MAD/MARD) value of 16.3. This combined measure used absolute differences for glucose values below 100 mg/dL and relative differences for higher readings.

Additionally, 69.8% of measurements fell within the study's predefined accuracy range of ±20 mg/dL for readings below 100 mg/dL or ±20% for higher readings. Approximately 86.3% met the wider ±30 mg/dL or ±30% criterion.

Researchers also evaluated clinical risk using the Parkes consensus error grid. About 69.9% of readings fell within zone A, while 29.1% fell within zone B. Another 1.0% fell within zone C, with none in the highest-risk zones D or E.

These findings suggest that most readings would carry limited clinical risk. Nevertheless, zone B results can still differ meaningfully from reference measurements.

Accuracy improved after the first week, suggesting that user familiarity or calibration stability may influence performance. No device-related adverse events were reported.

Although encouraging, these findings do not establish that the device can safely guide medication adjustments. Indeed, participants continued using conventional glucose measurements for treatment decisions throughout the investigation.

How Accuracy Compares With Established Glucose Monitors

Accuracy remains the biggest challenge for needle-free glucose technology.

Established CGM systems have demonstrated stronger analytical performance in clinical studies. For example, the Dexcom G7 has reported MARD values below 10% in clinical evaluations.

However, the GLUCUBE investigation used a combined MAD/MARD measure, so its overall value should not be treated as directly equivalent to conventional CGM MARD. Even with this distinction, the researchers concluded that the experimental system's precision remained below that of established CGM technology.

Another important concern involves glucose extremes.

The primary analysis excluded reference values below 70 mg/dL. Consequently, the study could not establish reliable performance during hypoglycemia, when accurate readings may be especially important.

Performance also declined at higher glucose concentrations. For readings above 180 mg/dL, MARD reached 21.4%, and fewer than half met the predefined ±20% accuracy criterion.

Furthermore, researchers compared measurements with a home glucose meter rather than a laboratory reference method. The study also involved relatively few participants at one center.

These limitations matter because incorrect readings can influence treatment decisions, particularly among patients taking insulin or medications that increase hypoglycemia risk.

The FDA has warned against unauthorized smartwatches and smart rings that independently claim to measure glucose without piercing the skin.

GLUCUBE is a different type of device, and the study reports that it subsequently obtained European CE marking. However, its stated intended use does not include guiding insulin dosing decisions. European marking should not be confused with FDA authorization.

What Comes Next for Needle-Free Glucose Testing

Despite current limitations, optical glucose measurement could eventually offer meaningful benefits.

For patients reluctant to perform finger sticks, an accurate needle-free option might encourage more frequent monitoring. Additionally, simple on-demand measurements could provide another way to observe glucose patterns between clinical visits.

Nevertheless, larger studies must establish whether these benefits translate into improved diabetes outcomes.

Future investigations should include more diverse populations, longer follow-up periods, and laboratory-based reference comparisons. Researchers must also examine performance during rapid glucose changes, hypoglycemia, and significant hyperglycemia.

Another priority involves reducing reliance on individual calibration. A device requiring repeated finger sticks during setup may still create barriers for some users.

For now, clinicians should explain the difference between promising experimental performance and proven treatment-guiding accuracy. Patients considering new monitoring technology should discuss appropriate options with a qualified healthcare professional through resources such as Healthcare.pro.

Ultimately, dependable results matter more than convenience alone.

Conclusion

Needle-free glucose technology continues to advance, and the latest GLUCUBE study suggests that near-infrared light can help estimate glucose during everyday activities.

However, its measurement accuracy remains below that of established CGM systems, particularly at higher glucose levels. Furthermore, the absence of sufficient hypoglycemia data limits conclusions about its safety during critical situations.

For now, needle-free systems may offer a complementary monitoring approach rather than a replacement for validated blood glucose meters or CGM devices.

Continued research could bring painless glucose testing closer to routine diabetes care, but clinical reliability must remain the priority.

Frequently Asked Questions

1. Can needle-free glucose monitors replace finger-stick tests?

Not yet for all clinical purposes. Current evidence does not establish that the GLUCUBE system can safely replace conventional glucose testing when making medication or insulin dosing decisions.

2. How does near-infrared glucose monitoring work?

The device sends near-infrared light through tissue and analyzes the resulting optical signals. Calibration algorithms then estimate glucose concentrations without drawing blood during routine measurements.

3. How accurate was the GLUCUBE device in the recent study?

Its combined MAD/MARD value was 16.3, with 69.8% of readings meeting the study's ±20 mg/dL or ±20% accuracy criterion. Accuracy was weaker at higher glucose levels.

4. Can people who use insulin rely on needle-free glucose monitors?

Investigational accuracy results are not sufficient to support insulin dosing decisions. People using insulin should follow their healthcare team's recommendations and rely on appropriately authorized glucose-monitoring systems.

5. When will completely needle-free glucose monitors become widely available?

Some devices have reached specific markets, but broader adoption depends on regulatory requirements, improved accuracy, and additional clinical evidence. No reliable timeline applies to all devices or countries.

This content is not medical advice. For any health issues, always consult a healthcare professional. In an emergency, call 911 or your local emergency services.